Progastrin-releasing peptide (ProGRP) is a tumor marker with benefits for the management of small-cell lung cancer patients. The assay is used to aid in the differential diagnosis in Lung Cancer and in the management of patients with small cell lung cancer in conjunction with other clinical methods. The results must be interpreted in conjunction with other methods in accordance with standard clinical guidelines.1
Lung cancer is the the most common cancers in the world with 2 millions new cases diagnosed every year.2 The two main histological types of the disease are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). It is important to distinguish between these two subtypes as they have different treatments and prognoses. NSCLC (approx. 80 % of cases), when in the early stages, is curable with surgery. SCLC, however, is an aggressively spreading neoplasm of rapid growth that is usually only treatable with chemo and radiotherapy.3
ProGRP a sensitive, specific tumor marker for patients with small cell lung cancer (SCLC) both in limited (LD) and diffuse disease (DD).4 ProGRP is also a tumor marker that can be used to assess response to therapy as well as to monitor recurrence of the disease.5
Benefits
- Specific tumor marker for SCLC, which supports differential diagnosis in lung cancer.6
- Lung cancer biomarkers available on a single automated platform - Elecsys® CEA, Elecsys® CYFRA 21-1, Elecsys® NSE, Elecsys® ProGRP and Elecsys® SCC.
- Equivalent performance between plasma and serum for flexibility and convenience, thus offering advantages over existing assays.6
